KDM3A and Ewing sarcoma: Our studies identified a role for KDM3A in Ewing Sarcoma [13], and subsequently RMS [14, 15], and demonstrated efficacy of the pan-JHDM inhibitor JIB-04 [40], in both cancer types [15, 41].